Tagged with Bayer

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

UAE Drawing on two decades of experience within Bayer Consumer Health Middle East, and now as VP and head of the firm’s Middle East/Pakistan Cluster, Mohamed Galal discusses the transformative impact of the COVID-19 pandemic on the pharmaceutical landscape, Bayer Consumer Health’s strategic outlook in a region where healthcare awareness is…

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

Global Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing for the pharmaceutical industry, illustrating these benefits with industry case studies.   Smart manufacturing has entered the world of modern…

China A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s EUR 70 million manufacturing investment; the licensing agreement between Zhejiang Doer Biologics and BioNTech, and Moderna’s deal to develop and…

Belgium Werner De Prins oversees Bayer’s operations in Benelux, a significant region for the global group with over 2000 employees, a turnover of around EUR 1.2 billion and 10 different sites across pharmaceuticals, crop science and consumer health, covering marketing & sales, R&D, and production with a global reach. De Prins…

Germany While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team in place. Former Roche Pharma head Bill Anderson is yet to lay out his strategic priorities as CEO of Bayer…

Germany The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with California biotech, Surrozen.   German CDMO Rentschler’s chief executive, Frank Mathias, stepping down (Fierce Pharma) After seven years at the…

Germany A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the rare kidney disease immunoglobulin A nephropathy (IgAN).   Bayer’s hunt…

Egypt Under the auspices of a wide-ranging Vision 2030 economic transformation plan, Egypt is moving towards covering the entirety of its 100 million plus population under a universal healthcare insurance scheme. Via direct presidential initiatives, the country has also made significant progress in tackling diseases like hepatitis C and breast cancer,…

Egypt Bayer’s Hatem Ismail introduces the company’s important work to help Egypt meet its ambitious Vision 2030 transformation goals; its significant footprint in the country across innovative pharmaceuticals, OTC drugs, and crop science products; and his bold ambitions for the affiliate’s future growth.   Bayer Egypt probably has one of the…

Mexico Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers, some industry insiders are bemoaning the current government’s healthcare missteps along with the country’s low public spending and regulatory hurdles.…